DEF: PepGen Inc. Schedules 2026 Annual Meeting

PepGen Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 18, 2026, to elect directors and ratify auditors.

Summary

• PepGen Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 18, 2026.
• The meeting's primary purposes are to elect three Class I directors and to ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Stockholders of record as of April 21, 2026, are eligible to vote.
• Proxy materials are being furnished to stockholders over the Internet, with a Notice of Internet Availability of Proxy Materials being mailed around April 29, 2026.
• The company is an emerging growth company and is utilizing scaled disclosure requirements.
• The board of directors is divided into three classes with staggered three-year terms.
• The company has adopted a Code of Business Conduct and Ethics and has entered into indemnification agreements with its directors and officers.
• The audit committee has reviewed the 2025 financial statements and recommended their inclusion in the Form 10-K.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily concerns routine annual meeting matters and corporate governance, without significant new financial or strategic disclosures.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and stockholder engagement.
• The board of directors is composed of individuals with extensive experience in the life sciences industry.
• The company has robust policies in place for director independence, corporate governance, and risk oversight.
• The audit committee has reviewed the financial statements and confirmed the independence of the auditors.
• The company has obtained insurance to cover potential liabilities for officers and directors.

Negatives

• The staggered board structure may delay or prevent stockholder efforts to effect a change in management or control.
• Dr. Joshua Resnick, a director, attended one less meeting than necessary to achieve 75% attendance in 2025.
• Late filings of Form 4s for Paul Streck, James McArthur, and Noel Donnelly related to option repricing due to administrative error.

Risks

• The staggered board structure may delay or prevent stockholder efforts to effect a change in management or control.
• The company faces risks as described in its 2025 Annual Report, which are managed by the board of directors and management.
• Potential for broker non-votes on Proposal No. 1 (election of directors) if beneficial owners do not provide voting instructions.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It outlines the agenda for the upcoming annual meeting and details corporate governance matters.

Management Comments

• On behalf of our Board of Directors and all our employees, thank you for your continued support and investment in PepGen Inc.
• We believe that having separate positions [Chair and CEO] is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance.
• Management is responsible for the day-to-day management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management.

Industry Context

StockSavvy.ai notes that PepGen Inc.'s proxy statement reflects standard corporate governance practices for a publicly traded biotechnology company, including the election of directors, ratification of auditors, and disclosures on executive compensation and related-party transactions. The company's focus on emerging growth company status and scaled disclosures is typical for companies at its stage.

Corporate Governance

Related Party Transactions

• License Agreement with Oxford University Innovation Limited (OUI) and Medical Research Council (MRC) for EDO peptides and related technology, involving royalty payments and milestone payments.
• Entities affiliated with RA Capital Management GP, LLC acquired shares in the 2024 Follow-on Offering and the 2025 Offering.
• Indemnification agreements have been entered into with each director.

Stakeholder Impact

• Shareholders: The election of directors and ratification of auditors are key governance matters impacting shareholder rights and oversight.
• Employees: Executive compensation details and benefit plans are disclosed, impacting employee morale and retention.
• Directors and Officers: Indemnification agreements and compensation policies are detailed, affecting their willingness to serve and potential liabilities.

Next Steps

• Stockholders to vote on the election of three Class I directors.
• Stockholders to ratify the appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2026.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Form 8-K within four business days.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting, focusing on director elections and auditor ratification. It does not contain new financial results, strategic shifts, or significant operational updates that would warrant a buy or sell recommendation. The information provided is standard for corporate governance and does not offer a basis for a change in investment strategy.

Keywords

PepGen Inc., Annual Meeting, Proxy Statement, Director Election, KPMG LLP, Independent Auditor, Corporate Governance, Stockholders, Virtual Meeting, Emerging Growth Company